Skip to main content
. 2024 Jul 6;16:154. doi: 10.1186/s13195-024-01521-9

Fig. 4.

Fig. 4

Flow-chart comparing DMT eligibility screening strategies. Analysis of predicted versus actual treatment decisions had P-tau217 been used to determine Aβ positivity in Butler MAP participants treated with aducanumab (n = 25), alongside Aβ negative controls (n = 12). A One-cutoff predictions compared to actual treatment decisions. B Two-cutoff predictions compared to actual treatment decisions. %Correct is calculated by comparing model predictions to the clinical decision to treat with aducanumab based on Aβ-PET/CSF testing. N = 37